Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
07 June 2022 | Story Prof Felicity Burt, Prof Dominique Goedhals and Dr Charles Kotzé
Prof Felicity Burt, Dr Charles Kotze and Prof Dominique Goedhals
From the left; Prof Felicity Burt, Dr Charles Kotzé and Prof Dominique Goedhals.

Opinion article by Prof Felicity Burt , Prof Dominique Goedhals , Division of Virology at the University of the Free State (UFS), and Dr Charles Kotzé, National Health Laboratory Service (NHLS), Universitas Academic Hospital.
The recent COVID-19 pandemic has certainly highlighted the importance of vigilance and awareness of emerging diseases with public health implications. The monkeypox virus has recently made headlines, after the detection of more than 200 cases in geographically distinct regions. On 13 May, the World Health Organisation (WHO) was notified of human cases of the monkeypox disease occurring in the United Kingdom, outside of the known endemic region.

Exported cases have been detected previously and usually occur sporadically. In contrast, within the past two weeks, human cases have been confirmed in at least 21 countries, including various European countries, the United Kingdom, Israel, the Canary Islands, Canada and the United States, and Australia. The initial case appears to have been a traveller from Nigeria. Sequence data may help to determine if there have been multiple exportations from West Africa. 

What is monkeypox and what do we know

What is monkeypox and what do we know about the aetiologic agent? Monkeypox is the name given to a disease caused by the monkeypox virus, a zoonotic pathogen endemic in Central and West Africa and responsible for cases of the disease in the endemic region, with occasional exported cases in travellers. The virus was initially identified in 1958 in monkeys housed at a research laboratory in Denmark, and the name monkeypox was derived from the appearance of lesions and the occurrence in monkeys. The first human case was identified 52 years ago in the Democratic Republic of the Congo. Since then, human monkeypox cases have been reported in several other Central and West African countries: Cameroon, the Central African Republic, Ivory Coast, the Democratic Republic of the Congo, Gabon, Liberia, Nigeria, Republic of the Congo, and Sierra Leone. The first monkeypox outbreak outside of Africa was in the United States of America in 2003 and was linked to contact with infected prairie dogs imported as exotic pets. Since then, there have been various small, contained outbreaks outside of Africa that have mostly been linked to the importation of the virus from African countries. 

The virus is related to the smallpox virus, which was eradicated in the 1970s by vaccination. Although belonging to the same family of viruses as the smallpox virus, the disease caused by monkeypox is less severe, with fewer fatalities.   Unlike smallpox, which carries a case fatality rate of 30%, the case fatality rate in monkeypox is low (estimated at 3-6% in more recent outbreaks).  There are two clades of the monkeypox virus: the West African clade and the Congo Basin (Central African) clade. In this outbreak, all of the cases have been linked to the West African clade of the monkeypox virus.

Transmission occurs from animal to human, and from human to human, through close contact with lesions, body fluids, and contaminated materials. The virus enters the body through the respiratory tract, mucous membranes, or broken skin.  The disease begins with non-specific symptoms such as fever, headache, muscle pains, and swollen lymph nodes. This is followed by the typical skin rash, which progresses through stages known as macules, then papules, vesicles, pustules, and lastly crusts or scabs. Lesions can also occur on mucous membranes such as the mouth, eye, and genital area.  The infectious period lasts through all stages of the rash, until all the scabs have fallen off. There are a number of other infectious and non-infectious conditions that need to be differentiated; therefore, individuals presenting with these symptoms will need to consult their doctor to determine whether a diagnosis of monkeypox needs to be considered. In the current outbreak, a number of the cases in the United Kingdom and Europe have been detected in men who have sex with men, during visits to sexual health clinics. This pattern of spread has not previously been described and it remains to be determined whether the spread has occurred through close person-to-person contact or through sexual transmission.  

Vaccination against smallpox virus offers 85% protection against monkeypox

To date, no cases have been detected in South Africa, but the recent global spread of the severe acute respiratory syndrome coronavirus 2 (SARS_CoV-2) highlights the ability of pathogens to spread. The National Institute for Communicable Diseases (NICD) in Johannesburg offers a specialised diagnostic service for the monkeypox virus, using molecular assays and electron microscopy. 

Vaccination against the smallpox virus is believed to offer 85% protection against monkeypox, hence older persons should have some protection; however, vaccination against smallpox was phased out globally following the eradication of smallpox during the 1970s. A more recently developed vaccine against monkeypox is available but has very limited availability.  No specific antivirals are available with proven efficacy in clinical trials.

While the monkeypox virus can be spread via the respiratory route, this occurs in the form of large droplets, rather than aerosol transmission, which is seen with SARS-CoV-2 (causing COVID-19). Aerosols are smaller particles that can remain suspended in the air for prolonged periods, facilitating the transmission of SARS-CoV-2. Monkeypox is therefore less contagious than COVID-19, as close contact is required for longer periods.  For this reason, many experts around the world predict that this outbreak will not spread like SARS-CoV-2. The importation of monkeypox to South Africa is a definite possibility, because South Africa is a significant economic and travel hub for Africa. Previous outbreaks of monkeypox in non-endemic areas have been interrupted by contact tracing and isolation, which was very effective in controlling further spread.  Heightened vigilance is therefore needed for the early detection of such cases.

News Archive

Applications for the Vice-Chancellor's Prestige Programme for 2013/2014 now open
2012-12-06

This highly prestigious programme, led by the Vice-Chancellor of the University of the Free State, seeks to identify, develop and promote the next cohort of the most promising and talented UFS academic members of staff who obtained a doctoral degree within the last five years. These are young scholars who have chosen academic careers and who are focused and determined to become senior academics in their respective disciplines.

Once identified, these scholars will be put through an intensive programme of academic and scholarship support that includes an advanced residential programme, exposure to leading scholars, intensive reading and writing programmes, high-level seminar participation and presentation, nuanced publication schedules and personal mentoring and advice.

The selection process is highly competitive, and aimed at those young scholars with the potential to obtain upper-level ratings (Y1 and P).  The selection criteria include the following:(1)

1. Recently obtained a PhD degree.
2. Evidence of an active publication record.
3. Early recognition of scholarly work, e.g. successful funding/grant applications and academic awards.
4. The early development of a post-doctoral intellectual project that shows evidence of scholarly “potential” (defined by the NRF Y-category).
5. Indication of the young scholar’s understanding of what their envisaged postdoctoral endeavours will contribute to the body of knowledge.
 
This period of support will run over a cycle of two years after which a new intake of next generation professors will be selected.
 
While this cohort will be selected for an intensive programme, ongoing development and support of all young scholars will continue. The selected scholars will reflect a balance of young academics from the humanities (broadly defined, including education, law, theology and the social sciences) and the natural sciences (broadly defined, including the agricultural and health sciences).
 
Call for Applications
This is a call for applications for the Vice-Chancellor’s Prestige Programme for 2013/2014. Candidates are invited to submit applications. No nomination is required, but deans and heads of department will also be asked to invite young scholars to apply.  Complete applications are due by Monday 21 January 2013. A full application will include the following documentation:

1. A complete curriculum vitae of the candidate.
2. A complete exercise of intent comprising the following:
2.1   Select two journal articles (copies of which to accompany the application) in the area you have identified for your intellectual focus post PhD. These articles have to be selected from journals of international standing in your field.
2.2   The articles need to be summarised (250 words each), and
2.3   Two questions have to be identified that you would want to pursue in relation to your intended project. 
2.4   This is followed by a brief, critical summary of a hundred lines maximum to indicate how these articles inform, integrate or provoke your planned future research.

Submission and contact address
A paper copy of the application must be submitted to the Vice-Chancellor’s secretary, Ms Melissa Coetzee, in the Main Building by 16:00 on Monday 21 January 2013 and an electronic copy of your entire application to the administrative assistant, Mr Albert Nell:nella@ufs.ac.za. You will be contacted to acknowledge receipt. Candidates will be informed of the outcome in February. Further information on the Vice-Chancellor’s Prestige Scholar Programme can be directed at any of the following co-directors (in alphabetical order):

Prof Jackie du Toit, Prof Neil Roos, Prof Aldo Stroebel or Prof Corli Witthuhn.
 
[1] The VC reserves the right to nominate young scholars to the programme and also to invite scholars to a panel interview to evaluate personal qualities, professional commitment and academic ambition.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept